Advertise on podcast: Dr. Paika Podcast

#PCOS #GLP1 #PMOS #Semaglutide #Tirzepatide Not losing weight on GLP-1 with PCOS? You're not imagining it, and it's not a willpower problem. In this video, I explain why semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) can stall in women with PCOS, now officially renamed PMOS (polyendocrine metabolic ovarian syndrome), and the 4 things doctors do to get weight loss moving again. You'll learn the 3 hormonal roadblocks behind a PCOS stall (high insulin, androgens and belly fat, and your own GLP-1 system), why standard dosing often isn't enough, how tirzepatide compares with semaglutide, when metformin or inositol makes sense, which labs to track (fasting insulin, HOMA-IR, free testosterone, SHBG, TSH, A1c and lipids), and how to tell your treatment is working even when the scale isn't. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter Timestamps 00:00 Why GLP-1 weight loss stalls with PCOS00:55 About me01:21 PCOS is now PMOS: why the name changed02:36 Insulin resistance in PCOS: the numbers03:12 Roadblock #1: Hyperinsulinemia04:44 Roadblock #2: Androgens and belly fat06:10 Muscle: a shortcut around insulin resistance06:57 Roadblock #3: Your own GLP-1 system07:55 Why standard GLP-1 dosing stalls09:11 Metabolic adaptation and normal plateaus09:51 Fix #1: Right drug, right dose10:36 Tirzepatide vs semaglutide (and PCOS data)11:39 Retatrutide11:56 Pregnancy and birth control on GLP-1s12:22 Fix #2: Metformin, combination therapy and inositol13:57 Fix #3: Labs to track, not just the scale15:33 Fix #4: Body composition and protecting muscle16:39 Non-scale wins to watch17:09 GLP-1 Masterclass17:30 Summary and what happens if you stop References 1. Teede HJ, et al. 2023 International Evidence-based Guideline for PCOS. J Clin Endocrinol Metab. 2023;108(10):2447-2469.2. PCOS renamed PMOS. The Lancet, May 12, 2026; Monash/MCHRI terminology summary, 2026.3. Stepto NK, et al. Hum Reprod. 2013;28(3):777-784.4. Cassar S, et al. Hum Reprod. 2016;31(11):2619-2631.5. Nestler JE. Semin Reprod Endocrinol. 1997;15(2):111-122.6. O'Reilly MW, et al. J Clin Endocrinol Metab. 2017;102(9):3327-3339.7. Zhu S, et al. Front Endocrinol. 2021;12:697223.8. Karolinska Institutet doctoral thesis on adipocyte lipolysis in PCOS.9. Moro C, et al. J Clin Endocrinol Metab. 2009;94(7):2579-2586.10. Aydin K, et al. Clin Endocrinol. 2014;81(4):588-592.11. Güneşli I, et al. Endocrine Abstracts. 2025;110:RC5.2.12. An impaired GLP-1 response is associated with prediabetes in PCOS with obesity. PMC6833370.13. Glintborg D, et al. Endocr Connect. 2017;6(4):267-277.14. Wegovy (semaglutide) US Prescribing Information, including Wegovy HD 7.2 mg (FDA, 2026).15. Zepbound (tirzepatide) US Prescribing Information.16. Carmina E, Longo RA. J Clin Med. 2023;12(18):5921.17. Alawami F, et al. Ir J Med Sci. 2026;195(1):131-136.18. Fothergill E, et al. Obesity. 2016;24(8):1612-1619.19. Thomas MK, et al. J Clin Endocrinol Metab. 2021;106(2):388-396.20. Tirzepatide vs semaglutide on beta-cell function and insulin sensitivity. J Clin Endocrinol Metab. 2024;109(12):3046-3054.21. Aronne LJ, et al. SURMOUNT-5. N Engl J Med. 2025;393(1):26-36.22. Clift AK, et al. J Endocr Soc. 2026;10(9):bvag177.23. PERIODS trial (tirzepatide in PCOS). ClinicalTrials.gov NCT07326111.24. Jastreboff AM, et al. TRIUMPH-1 (retatrutide). N Engl J Med. 2026.25. Jensterle M, et al. Exp Ther Med. 2016;11(4):1194-1200.26. Zhang W, et al. Metab Target Organ Damage. 2026;6:10.27. Fitz V, et al. J Clin Endocrinol Metab. 2024;109(6):1630-1655.28. Matthews DR, et al. Diabetologia. 1985;28(7):412-419.29. Ding X, et al. Front Endocrinol. 2018;9:700.30. Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002; Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216.31. Jensterle M, et al. Front Endocrinol. 2024;15:1366940. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Testosterone #TRT #LowTestosterone #GLP1 #weightloss  Is “male menopause” real, and do you actually need testosterone therapy? As an internal medicine and obesity medicine physician, I break down what the research really shows about low testosterone after 50, including: How common true late-onset hypogonadism actually is (hint: far less than the ads suggest)Why excess weight is the #1 fixable cause of low testosterone, and how GLP-1s like Ozempic and Mounjaro may help your own testosterone come backHow to get tested properly (morning, fasting, repeated)What TRT can and can’t do, according to the Testosterone TrialsWhat the TRAVERSE trial showed about heart safety, plus the side effects that did go upThe newest FDA label changes and the HHS proposalA simple 5-question checklist to work through with your doctor before you ever start TRT 📘 FREE GLP-1 Diet Cookbook (high-protein meals for a smaller appetite): https://drmohammedpaika.com/newsletter 🎓 GLP-1 Masterclass (calorie and protein targets, side effects, and a 12-week home strength program): https://drmohammedpaika.com This video is for educational purposes only and is not medical advice. Talk to your own doctor before starting, stopping, or changing any medication. TIMESTAMPS0:00 Is low testosterone really the answer?1:34 Is “male menopause” even real?3:13 The biggest driver of low testosterone: weight4:04 How GLP-1s may raise your own testosterone5:00 The other side: semaglutide and low T6:03 How to know if you actually have low testosterone7:28 What TRT really does: the Testosterone Trials8:54 Is testosterone safe for your heart? (TRAVERSE)10:29 FDA label changes and the HHS proposal11:04 On a GLP-1 and testosterone at the same time?12:06 Should everyone consider hormone therapy?13:08 5 questions to ask before starting TRT14:24 What to watch next 📚 REFERENCES Gray A, et al. Massachusetts Male Aging Study. J Clin Epidemiol. 1991;44:671-684.Feldman HA, et al. Massachusetts Male Aging Study. J Clin Endocrinol Metab. 2002;87:589-598.Wu FCW, et al. European Male Ageing Study: late-onset hypogonadism. N Engl J Med. 2010;363:123-135.Corona G, et al. Weight loss and obesity-associated hypogonadism (meta-analysis). Eur J Endocrinol. 2013;168:829-843.Portillo-Canales S, Dhindsa S, et al. Incretin-based drugs and testosterone in men. ENDO 2025 abstract RF27-03; Endocr Pract. 2026;32:696-703.Liao B, Able C, et al. Semaglutide and hypogonadism/ED in non-diabetic men. SMSNA 2023 abstract 157; Able C, et al. Int J Impot Res. 2024.Bhasin S, et al. Testosterone therapy in men with hypogonadism: Endocrine Society guideline. J Clin Endocrinol Metab. 2018;103:1715-1744.Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423-432.Snyder PJ, et al. Effects of testosterone treatment in older men (Testosterone Trials). N Engl J Med. 2016;374:611-624.Qaseem A, et al. Testosterone treatment in men with age-related low testosterone: ACP guideline. Ann Intern Med. 2020;172:126-133.Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023;389:107-117.Snyder PJ, et al. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390:203-211.U.S. FDA. Class-wide labeling changes for testosterone products. Feb 28, 2025.U.S. HHS. Request to update testosterone replacement therapy labeling. June 18, 2026 (proposed).U.S. FDA. Removal of boxed warnings on menopausal hormone therapy. Nov 2025.Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002.Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Microdosing #Zepbound #Ozempic #WeightLossMaintenance Microdosing Zepbound & Ozempic: How Low Can You Go and Still Keep the Weight Off? You hit your goal weight. Now the question is: do you have to stay on this dose forever? More and more people are cutting their GLP-1 dose to a fraction or stretching their shots to every 10 to 14 days, hoping to save money, cut side effects, and keep the weight off. I'm Dr. Mohammed Paika, a board-certified internal medicine and obesity medicine physician and practicing hospitalist. In this video I break down what the research actually shows about lower-dose GLP-1 maintenance, and what it doesn't show yet. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter TIMESTAMPS0:00 Do I have to stay on this dose forever?1:24 The rebound: what happens when you stop2:49 Why microdosing is trending now4:01 What is microdosing? The minimal effective dose5:02 Two approaches: dose reduction vs. interval spacing6:01 What happens at lower doses7:35 Muscle preservation9:14 What the evidence says: SURMOUNT-MAINTAIN12:03 Why the weight comes back: the set point13:35 Why people want a lower dose: cost, supply, side effects14:16 The 4 risks of going too low17:06 My step-down framework18:38 How low can you go? The bottom line REFERENCES1. Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564.2. Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38-48.3. SURMOUNT-4 post hoc analysis of weight regain. JAMA Intern Med. 2025.4. Evidation. Real-world GLP-1 dosing behaviors (preliminary survey). December 2025.5. Bickel CS, Cross JM, Bamman MM. Exercise dosing to retain resistance training adaptations in young and older adults. Med Sci Sports Exerc. 2011;43(7):1177-1187.6. Wegovy (semaglutide), Ozempic (semaglutide) and Zepbound (tirzepatide) US prescribing information.7. Hackensack Meridian Health. Is microdosing GLP-1s safe? May 2026.8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409-1439.9. Nauck MA, et al. Rapid tachyphylaxis of the GLP-1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60(5):1561-1565.10. O'Neil PM, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.11. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.12. Wilding JPH, et al. STEP 1 body composition (DXA) substudy. J Endocr Soc. 2021;5(Suppl 1):A16-A17.13. Look M, et al. SURMOUNT-1 body composition (DXA) substudy. Diabetes Obes Metab. 2025.14. SURMOUNT-MAINTAIN. Tirzepatide maximum dose vs. 5 mg vs. placebo for weight maintenance. Lancet. May 2026.15. Gudbergsen H, et al. Semaglutide with a digital weight-management program in Denmark (Embla), lowest effective dose. 2025.16. Embla semaglutide tapering study. European Congress on Obesity. 2024.17. ClinicalTrials.gov NCT07783854. Randomized dose-tapering regimen of semaglutide for weight-loss maintenance.18. Eli Lilly. ATTAIN-MAINTAIN topline results (orforglipron). December 2025.19. Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597-1604.20. Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612-1619.21. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. 2025.22. Eli Lilly. Zepbound KwikPen instructions for use and FAQ (priming). 2026.23. US FDA. Dosing errors with compounded semaglutide. July 26, 2024. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #Mounjaro #GLP1 #Tirzepatide #WeightLossDoctor Should you split your weekly Ozempic, Wegovy, Mounjaro, or Zepbound shot into two smaller doses? Lots of you have asked me about this in the comments. People split their dose to ease the nausea in the first few days and keep food noise down late in the week. In this video, I explain what the pharmacokinetics predict, what the clinical trials did and didn’t test, and the hidden risks most people never hear about. As an obesity medicine physician, I walk you through half-life, steady state, peak and trough levels, and a simple model of what splitting does to your drug levels. Then I cover the safer, approved ways your doctor can smooth out your week instead. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com ⚠️ This video is for education only and is not personal medical advice. Don’t change your dose, your schedule or your device without talking to the clinician who prescribes it. TIMESTAMPS0:00 Should you split your weekly GLP-1 dose?1:17 Why people split their dose: the peak and the trough2:56 Half-life and steady state3:27 What splitting does to your drug levels5:11 Side effects: the peak or the dose increase?6:09 What the clinical trials actually tested7:52 Plausible vs. proven8:21 Hidden risks: pens and vials9:16 Compounded vials and dosing errors10:44 Strategy 1: Slow the titration11:23 Strategy 2: Find your lowest effective dose11:56 Strategy 3: Eat around injection day12:35 Strategy 4: Timing and short-term support12:58 Strategy 5: Change the molecule13:45 The verdict14:14 3 questions for your doctor REFERENCES Wegovy (semaglutide) US Prescribing Information, Novo Nordisk. https://www.novo-pi.com/wegovy.pdfZepbound (tirzepatide) US Prescribing Information, Eli Lilly. https://medlibrary.org/lib/rx/meds/zepbound/page/5/Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.Wharton S, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg. Diabetes Obes Metab. 2022;24:94-105.Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.Aronne LJ, et al. Tirzepatide vs. semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025.O’Neil PM, et al. Semaglutide vs. liraglutide and placebo for weight loss (phase 2). Lancet. 2018;392:637-649.Frias JP, et al. Tirzepatide dose-escalation regimens. Diabetes Obes Metab. 2020;22:938-946.Huang KP, et al. Dissociable hindbrain GLP1R circuits for satiety and aversion. Nature. 2024;632:585-593.Lau J, et al. Discovery of the once-weekly GLP-1 analogue semaglutide. J Med Chem. 2015;58:7370-7380.Cengiz A, et al. Alternative dosing regimens of GLP-1 receptor agonists. Diabetes Obes Metab. 2025;27:2251-2258.Ji L, et al. GZR18 once-weekly or bi-weekly dosing: phase 1b/2a trial. Cell Rep Med. 2026;7:102743.FDA. Dosing errors associated with compounded injectable semaglutide (July 2024). https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compoundedISMP. Errors possible when microdosing (counting clicks) to dose weight loss medicines (2025). https://www.consumermedsafety.org/safety-articles/errors-possible-when-microdosing-counting-clicks-to-dose-weight-loss-medicinesLilly Medical: Zepbound single-dose vial and KwikPen guidance. https://medical.lilly.comAmerica’s Poison Centers semaglutide call data, as reported by CNN/ABC7 (Dec 2023). https://abc7ny.com/fda-poison-control-centers-weight-loss-drug-diabetes/14178159/Foundayo (orforglipron) US Prescribing Information, Eli Lilly.Ryan H, et al. OxyContin’s 12-hour problem. Los Angeles Times. 2016. Modeled peak and trough figures come from a simple one-compartment model built on label half-lives. They are illustrative estimates, not blood levels measured in a trial. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#FoodNoise #GLP1 #Ozempic #WeightLoss #ObesityMedicine Can't stop thinking about food, even right after a full meal? That constant chatter has a name: food noise. I explain what it is, why GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound quiet it, and why it often returns when people stop them. You'll learn the 2 drivers behind it, a simple test to tell real hunger from food noise, and 9 evidence-based strategies to turn it down, with or without medication. Every claim is referenced below. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS0:00 Can't stop thinking about food?1:32 Food noise vs. real hunger2:02 Why GLP-1s made food noise famous2:41 What happens when you stop semaglutide3:02 Your brain's 2 appetite systems4:13 Driver 1: Physical4:24 Pattern 1: Eating too little, too early7:20 Driver 2: Psychological7:30 Trigger 1: Habit (the Netflix effect)9:02 How sleep and stress turn up the volume9:29 The plain-food test: hunger or noise?9:57 9 strategies to quiet food noise10:07 1. Protein-forward breakfast10:31 2. Eat your carbs last10:58 3. Protect your sleep11:16 4. Edit your food cues11:39 5. Plan and prep once a week13:27 Your 7-day experiment13:42 When food noise is still loud: GLP-1 medications14:15 4 important caveats15:11 When it's more than noise REFERENCES1. Hayashi 2023, Nutrients: https://pubmed.ncbi.nlm.nih.gov/38004203/2. Blundell 2017, Diabetes Obes Metab: https://pmc.ncbi.nlm.nih.gov/articles/PMC5573908/3. van Bloemendaal 2014, Diabetes 63(12):41864. Wilding 2022, Diabetes Obes Metab: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9542252/5. Lutter 2009, J Nutr: https://pubmed.ncbi.nlm.nih.gov/19176746/6. Berridge 2009, Physiol Behav: https://pmc.ncbi.nlm.nih.gov/articles/PMC2717031/7. Boswell 2016, Obes Rev: https://canlab.yale.edu/sites/default/files/boswel-kober_2016_obesityreviews.pdf8. Wood & Neal 2007, Psychol Rev 114(4):8439. Keys 1950, The Biology of Human Starvation (Minnesota Starvation Experiment)10. Sumithran 2011, NEJM: https://pubmed.ncbi.nlm.nih.gov/22029981/11. Rolls 2017, Nutr Bull: https://pubmed.ncbi.nlm.nih.gov/29151813/12. Dennis 2010, Obesity: https://pubmed.ncbi.nlm.nih.gov/19661958/13. World Health Organization 2023, Guideline on non-sugar sweeteners (May 15, 2023)14. Ludwig 1999, Pediatrics: https://pubmed.ncbi.nlm.nih.gov/10049982/15. Lennerz 2013, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/23803881/16. Weigle 2005, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/16002798/17. Hall 2019, Cell Metab: https://pubmed.ncbi.nlm.nih.gov/31105044/18. Leidy 2015, Am J Clin Nutr: https://pubmed.ncbi.nlm.nih.gov/25926512/19. Neal et al. 2011, Pers Soc Psychol Bull 37(11):142820. Tomova 2020, Nat Neurosci: https://dspace.mit.edu/handle/1721.1/13831321. Spiegel 2004, Ann Intern Med: https://pubmed.ncbi.nlm.nih.gov/15583226/22. Hoertel 2014, Nutr J: https://nutritionj.biomedcentral.com/articles/10.1186/1475-2891-13-8023. Leidy 2013, Am J Clin Nutr: https://pmc.ncbi.nlm.nih.gov/articles/PMC3718776/24. Tasali 2022, JAMA Intern Med: https://pubmed.ncbi.nlm.nih.gov/35129580/25. Hunter 2018, Appetite: https://pubmed.ncbi.nlm.nih.gov/29183701/26. Ducrot 2017, Int J Behav Nutr Phys Act: https://pubmed.ncbi.nlm.nih.gov/28153017/27. Lieberman 2007, Psychol Sci: https://pubmed.ncbi.nlm.nih.gov/17576282/28. Zaccaro 2018, Front Hum Neurosci: https://pubmed.ncbi.nlm.nih.gov/30245619/29. Gollwitzer & Sheeran 2006, Adv Exp Soc Psychol 38:6930. Taylor & Oliver 2009, Appetite 52(1):15531. Ledochowski 2015, PLoS One: https://pmc.ncbi.nlm.nih.gov/articles/PMC4356559/32. Buffey 2022, Sports Med: https://pubmed.ncbi.nlm.nih.gov/35147898/33. Wilding 2021, NEJM (STEP 1): https://www.nejm.org/doi/full/10.1056/NEJMoa203218334. Hudson 2007, Biol Psychiatry: https://pubmed.ncbi.nlm.nih.gov/16815322/35. Tataranni 1996, Am J Physiol: https://pubmed.ncbi.nlm.nih.gov/8770026/36. Shukla 2015, Diabetes Care: https://pmc.ncbi.nlm.nih.gov/articles/PMC4876745/ ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Menopause #Tirzepatide #Semaglutide #WeightLoss Not losing weight on a GLP-1 after menopause? You’re not imagining it, but your body isn’t broken and the medication hasn’t stopped working. In this video, I’m Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. I break down what the research really shows about GLP-1s like tirzepatide (Mounjaro, Zepbound) and semaglutide (Ozempic, Wegovy) after menopause. You’ll learn what menopause does to fat, muscle and metabolism, and how much weight women actually lose at each stage of menopause in the clinical trials. I’ll show you why real-world results can lag, what the newest hormone therapy studies show and why they don’t prove cause and effect, and how to protect your muscle and bones. I’ll also walk you through the 5-step plan I use with my midlife patients. 📩 FREE GLP-1 Diet Cookbook + Weekly Newsletterhttps://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com  TIMESTAMPS0:00 Why weight loss feels harder after menopause1:56 What menopause does to your body4:15 Do GLP-1s still work after menopause?7:12 Why it feels harder in real life9:06 Hormone therapy and GLP-1s: what the data shows11:21 Free GLP-1 Diet Cookbook11:44 Protecting your muscle and bones13:42 GLP-1 Masterclass14:12 The 5-step midlife GLP-1 plan15:35 A real viewer example16:41 Final thoughts 📚 REFERENCESGreendale GA, et al. Changes in body composition and weight during the menopause transition (SWAN). JCI Insight. 2019;4(5):e124865.Lovejoy JC, et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6):949-958.Pontzer H, et al. Daily energy expenditure through the human life course. Science. 2021;373(6556):808-812.Karppinen JE, et al. Age but not menopausal status is linked to lower resting energy expenditure. J Clin Endocrinol Metab. 2023;108(11):2789-2797.Thomson ZO, et al. Weight loss outcomes in premenopausal versus postmenopausal women during behavioral weight loss interventions. Menopause. 2021;28(3):337-346.Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage (SURMOUNT post hoc). Obesity. 2025;33:851-860.García-Pérez LE, et al. Tirzepatide weight reduction by sex: SURMOUNT-1 to -4 post hoc. Presented at EASD 2024.Castaneda R, et al. Sex, not age, predicts weight loss outcomes with tirzepatide. Obesity. 2026;34(Suppl 2):132-145.Huvinen E, et al. Body weight loss with semaglutide 7.2 mg is independent of menopausal status (STEP UP post hoc). Presented at the European Congress on Obesity, 2026.Castaneda R, et al. Impact of reproductive stage and menopausal hormone therapy on weight loss outcomes with tirzepatide. Presented at The Menopause Society Annual Meeting, 2025.Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153(7):435-441.Hurtado MD, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31:266.Castaneda R, et al. Menopause hormone therapy and tirzepatide-associated weight loss in postmenopausal women. Lancet Obstet Gynaecol Womens Health. 2026;2(2):e118-e128.Hurtado MD, et al. Semaglutide reduces body weight regardless of menopause status (STEP and OASIS 4 post hoc). Presented at ObesityWeek, 2025.Papadakis GE, et al. Menopausal hormone therapy is associated with reduced total and visceral adiposity (OsteoLaus). J Clin Endocrinol Metab. 2018;103(5):1948-1957.Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.Look M, et al. Body composition changes during weight reduction with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.Jensen SBK, et al. Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment. JAMA Netw Open. 2024;7(6):e2416775.Watson SL, et al. High-intensity resistance and impact training in postmenopausal women with low bone mass (LIFTMOR). J Bone Miner Res. 2018;33(2):211-220. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Wegovy #Zepbound #WeightLoss Why GLP-1 Medications Cause Extreme Fatigue (And How to Fix Low Energy) Are you exhausted on Ozempic, Wegovy, Mounjaro, or Zepbound? You’re not imagining it. Fatigue is listed in the prescribing information, and it’s one of the most common complaints I see in the comments. In this video, I’m Dr. Mohammed Paika, an internal medicine and obesity medicine physician. I break down the 4 biological reasons GLP-1 medications can leave you drained: unintentional undereating, quiet dehydration, the drug’s effects on the brain, and nutrient deficiencies like low iron and B12. Then I walk you through 4 practical fixes: a calorie and protein floor, a hydration plan that goes beyond plain water, the blood work to ask your doctor for, and how to talk to your prescriber about dose and titration. I finish with the warning signs that mean you need to be seen right away. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter This video is for education only and is not personal medical advice. Talk to your own clinician before changing your diet, fluids, supplements, or medication. TIMESTAMPS0:00 Why you feel exhausted on a GLP-12:00 Who I am and why I made this video3:09 Is the drug toxic? What the trials show4:35 Cause #1: Running on empty7:43 Cause #2: The thirst signal goes quiet10:35 Cause #3: The drug talks to your brain12:52 Cause #4: The deficiency nobody tests for15:27 Fix #1: Set a calorie and protein floor18:01 Fix #2: Hydrate beyond plain water19:44 Fix #3: The blood work to ask for21:10 Fix #4: Slow the dose down, don’t quit22:36 Red flags: when to get seen urgently REFERENCES Wegovy (semaglutide) Prescribing Information. FDA, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdfZepbound (tirzepatide) Prescribing Information. https://uspl.lilly.com/zepbound/zepbound.html; Jastreboff AM, et al. N Engl J Med. 2022;387:205–216 (SURMOUNT-1).Friedrichsen M, et al. Diabetes Obes Metab. 2021;23:754–762. https://doi.org/10.1111/dom.14280Prado CM, et al. Lancet Diabetes Endocrinol. 2024;12:785–787. https://doi.org/10.1016/S2213-8587(24)00272-9Winzeler B, et al. J Clin Invest. 2021;131:e151800. https://jci.org/articles/view/151800Gutzwiller JP, et al. Digestion. 2006;73:142–150.Gabery S, et al. JCI Insight. 2020;5:e133429. https://insight.jci.org/articles/view/133429Butsch WS, et al. Obesity Pillars. 2025;15:100186. https://doi.org/10.1016/j.obpill.2025.100186Mozaffarian D, et al. Am J Clin Nutr. 2025;122:344–367. https://doi.org/10.1016/j.ajcnut.2025.04.023Aroda VR, et al. J Clin Endocrinol Metab. 2016;101:1754–1761. https://pmc.ncbi.nlm.nih.gov/articles/PMC4880159Westerterp-Plantenga MS, et al. J Appl Physiol. 1999;87:391–399. https://pubmed.ncbi.nlm.nih.gov/10409600/Paika MK. GLP-1 Masterclass; The Weight Equation; GLP-1 Diet Cookbook. https://drmohammedpaika.com ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Semaglutide #AlcoholUseDisorder #WeightLoss People on Ozempic and Wegovy are reporting a side effect that isn't on the label: they're losing interest in alcohol. Is it real, or just nausea? As an internal medicine and obesity medicine physician, I work this up like an unexplained finding in a hospital patient. We'll look at the patient reports and real-world data, consider every possible explanation, read the newest trials (including the 2026 Lancet trial), and finish with a practical plan. In this video you'll learn:Why GLP-1 drugs may turn down cravings, and what "food noise" really isWhat the Lancet, JAMA Psychiatry and earlier trials actually foundWhy the first human trial failed, and how it shaped the one that workedWhat we still don't know before this becomes a standard treatment5 safety rules if you drink while on a GLP-1 TIMESTAMPS0:00 – A strange answer on the admission form1:44 – What patients are reporting (and what the data shows)3:20 – Why this matters: the alcohol treatment gap4:43 – Three possible explanations7:43 – How GLP-1s act on the brain: the two buttons10:36 – Protecting your muscle on a GLP-111:17 – The 2026 Lancet trial12:43 – The lab trial: what changed and what didn't13:53 – The trial that failed, and what it taught us15:33 – Animal research foundations16:28 – Would I prescribe it for alcohol today?18:46 – 5 rules before your next drink on a GLP-120:30 – Treatments that already work21:46 – Final thoughts and resources 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter REFERENCESKlausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity. Lancet. 2026;407(10540):1687–1698. https://doi.org/10.1016/S0140-6736(26)00305-3Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405.Klausen MK, et al. Exenatide once weekly for alcohol use disorder. JCI Insight. 2022;7(19):e159863. https://insight.jci.org/articles/view/159863Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for alcohol use disorder. JAMA Psychiatry. 2025;82(1):94–98.Wang W, Volkow ND, et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder. Nat Commun. 2024;15:4548. https://doi.org/10.1038/s41467-024-48780-6Quddos F, et al. Physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Sci Rep. 2025. https://doi.org/10.1038/s41598-025-17927-wSuchankova P, et al. The GLP-1 receptor as a potential treatment target in alcohol use disorder. Transl Psychiatry. 2015;5:e583. https://www.nature.com/articles/tp201568Thomsen M, et al. GLP-1 analogs and alcohol intake in vervet monkeys. Psychopharmacology. 2019;236:603–611.Aranäs C, et al. Semaglutide reduces alcohol intake and relapse-like drinking in rats. eBioMedicine. 2023;93:104642.Leggio L, et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat Med. 2023;29:2993–2995.Berridge KC, Robinson TE. Liking, wanting, and the incentive-sensitization theory of addiction. Am Psychol. 2016;71(8):670–679.Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N Engl J Med. 2016;374:363–371.Wilding JPH, et al. Weight regain after withdrawal of semaglutide: STEP 1 extension. Diabetes Obes Metab. 2022;24(8):1553–1564.Jonas DE, et al. Pharmacotherapy for adults with alcohol use disorders. JAMA. 2014;311(18):1889–1900.Han B, et al. Use of medications for alcohol use disorder in the US. JAMA Psychiatry. 2021;78(8):922–924.World Health Organization. Global status report on alcohol and health. 2024.U.S. Surgeon General. Alcohol and Cancer Risk Advisory. 2025. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Retatrutide #GLP3 #WeightLoss #GLP1 #ObesityMedicine How long does retatrutide actually stay in your system? Retatrutide, the triple-hormone drug people call "GLP-3" or "reta," has a half-life of about 6 days. That one number explains when side effects hit and why the dose has to climb slowly. It also explains why a short pause before surgery may not be enough, and why the drug lingers for about a month after your last shot. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine. In this video, I walk you through the 4 clocks retatrutide sets in your body and what the phase 3 trials really show, including up to 30.3% weight loss. You'll learn about the side effects people aren't talking about, like changes in skin sensation and heart rate. I also explain why the "research use only" vials sold online are a serious risk. Retatrutide is not FDA-approved. The regulated routes are a clinical trial, Lilly's limited early access program (through your doctor) or waiting for approval. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS00:00 The ER patient who "wasn't taking anything"01:42 What retatrutide is: 3 signals instead of 202:34 What the trials show03:20 Is retatrutide FDA-approved? How people get it legally04:02 Retatrutide's half-life: about 6 days04:27 Why it lasts so long05:07 Clock 1: the 7-day clock and side effects06:13 The new side effect: dysesthesia06:52 Heart rate and heart safety07:30 Missed dose: there's no official rule08:11 Clock 2: building up to steady state08:50 How the trials raised the dose09:43 Why vials make dosing dangerous10:34 Clock 3: how long retatrutide stays in your system11:31 What changes how fast you clear it12:26 Why side effects don't stop when you stop12:57 Surgery, endoscopy and sedation13:42 Pregnancy and contraception14:15 The vial problem: "research use only"14:57 What's really in the vial?15:41 My position as your doctor17:11 Clock 4: what happens when you stop17:37 Why your body defends its old weight18:21 What the stopping data shows18:55 My own weight-regain story19:42 Muscle is the real stake20:31 The plan21:27 Protecting your muscle on GLP-1s REFERENCES (FULL LIST AVAILABLE ON REQUEST) Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b trial. Lancet. 2022;400:1869–1881. https://www.sciencedirect.com/science/article/abs/pii/S0140673622020335Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514–526. https://www.nejm.org/doi/full/10.1056/NEJMoa2301972Eli Lilly and Company. Retatrutide TRIUMPH-4 phase 3 results. December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-averageEli Lilly and Company. TRIUMPH-2 and TRIUMPH-3 results; BLA planned Q1 2027. July 23, 2026. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additionalSanyal AJ, et al. Retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. https://www.nature.com/articles/s41591-024-03018-2Axios. Unapproved obesity drug spawns a black market frenzy. August 24, 2026. https://www.axios.com/2026/08/24/unapproved-obesity-drug-spawns-a-black-market-frenzyThe Partnership for Safe Medicines. The retatrutide black market: patient safety groups warn of growing risks. August 2026. https://www.safemedicines.org/2026/08/reta-groups-warn-understudied-drugs.htmlFinnrick. Retatrutide testing results (accessed October 2026). https://www.finnrick.com/products/retatrutide ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #WeightLoss #Ozempic #Mounjaro #ObesityMedicine Not losing weight on a GLP-1? The problem usually isn't you, and it usually isn't the medication either. It's the variables nobody checked. I'm Dr. Mohammed Paika, a physician board-certified in Internal Medicine and Obesity Medicine. I've spent about 15 years as a hospitalist, and I'm also a certified personal trainer and nutrition coach. In this video, I walk you through 8 evidence-based reasons the scale can stall on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound), plus a bonus. They range from diabetes and insulin resistance to medications that quietly cause weight gain, eating too little, muscle loss, sleep apnea and dose problems. At the end, I share my 4-question test to tell whether your GLP-1 is working, stalling or needs to be changed. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com ⏱️ TIMESTAMPS0:00 Why your GLP-1 isn't working (the 2 a.m. patient)1:47 Reason 1: Your starting point was different3:47 Reason 2: Diabetes, insulin resistance and PCOS5:13 Reason 3: Medications quietly working against you6:57 Reason 4: You're eating too little, not too much8:47 Reason 5: The quiet calorie creep10:07 Free GLP-1 Diet Cookbook10:33 Reason 6: You're losing muscle, and the scale can't tell you12:29 Reason 7: The exercise myth, and what works instead14:06 GLP-1 Masterclass14:41 Reason 8: Sleep, stress and sleep apnea15:55 Bonus: Dose, timing, injection site and refills17:35 The 4-question test: is your GLP-1 working?19:36 What to watch next 📚 REFERENCES Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.Davies M, et al. Semaglutide 2.4 mg in adults with overweight or obesity and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.Garvey WT, et al. Tirzepatide in people with obesity and type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.Look M, et al. Body composition changes with tirzepatide in SURMOUNT-1. Diabetes Obes Metab. 2025.Mosenzon O, et al. Clinically relevant weight loss independent of early response to semaglutide 2.4 mg (STEP 4). J Endocr Soc. 2021;5(Suppl 1).Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232.Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.Lichtman SW, et al. Discrepancy between self-reported and actual caloric intake and exercise in obese subjects. N Engl J Med. 1992;327:1893-1898.Nedeltcheva AV, et al. Insufficient sleep undermines dietary efforts to reduce adiposity. Ann Intern Med. 2010;153:435-441.Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24:1612-1619.LaForgia J, et al. Effects of exercise intensity and duration on excess post-exercise oxygen consumption. J Sports Sci. 2006;24:1247-1264.Pontzer H, et al. Constrained total energy expenditure and metabolic adaptation to physical activity. Curr Biol. 2016;26:410-417.Greendale GA, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4:e124865.Magkos F, et al. Effects of moderate and subsequent progressive weight loss on metabolic function. Cell Metab. 2016;23:591-601.Wegovy (semaglutide) and Zepbound (tirzepatide) U.S. Prescribing Information.Paika MK. GLP-1 Masterclass. 2026.Paika MK. The Weight Equation: A Physician's Guide to the Science and Treatment of Obesity. 2026. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Tirzepatide #Mounjaro #Zepbound #GLP1 #WeightLoss How long does tirzepatide (Mounjaro, Zepbound) actually stay in your system? It's not 5 days. In this video, I explain tirzepatide's half-life using 4 clocks it sets in your body. Those clocks explain when side effects hit and what to do if you miss a dose. They also explain why a 1-week pause before surgery may not be enough, why the birth control rule is 4 weeks, and how long the drug takes to clear after your last shot. Then we get to the clock that matters most: what happens after you stop. You'll see what the SURMOUNT-4 trial found about weight regain and why muscle loss is the real risk. I'll also share how I regained 45 pounds when my own structure disappeared, and the 2 paths that protect your results. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS00:00 Why "it's gone in 5 days" is wrong01:26 What tirzepatide is and how it works02:25 Half-life explained02:59 Why it lasts so long: albumin binding03:48 Clock 1: the 7-day clock04:18 Side effects: when they hit and how to ease them05:47 Why food noise returns at the end of the week06:14 Missed a dose? The 96-hour rule07:16 Clock 2: the 4-week clock and steady state08:06 Why your dose goes up in 2.5 mg steps09:05 Birth control: the 4-week rule10:09 Clock 3: how long tirzepatide stays in your system10:56 What makes clearance faster or slower12:39 Why severe side effects don't stop when you stop13:42 Surgery, colonoscopy and sedation15:07 Pregnancy planning15:35 Will it show up on a drug test?16:12 Clock 4: what happens when you stop16:46 Why your body fights weight loss17:36 SURMOUNT-4: stopping vs staying on17:58 My own weight-regain story18:48 The muscle problem19:51 The plan: 2 good paths21:17 Protecting your muscle on GLP-1s REFERENCESEli Lilly and Company. ZEPBOUND (tirzepatide) prescribing information. https://pi.lilly.com/us/zepbound-uspi.pdfKindel TL, et al. Multisociety clinical practice guidance for the safe use of GLP-1 receptor agonists in the perioperative period. 2024. https://www.cghjournal.org/article/S1542-3565(24)00910-8/fulltextAmerican Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients on GLP-1 receptor agonists. June 29, 2023. https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperativeAronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024;331(1):38–48. https://jamanetwork.com/journals/jama/fullarticle/2812936Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038Sumithran P, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365:1597–1604. https://pubmed.ncbi.nlm.nih.gov/22029981/Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. 2022. https://investor.lilly.com/news-releases/news-release-details/lillys-surmount-1-results-published-new-england-journal-medicineDeacon CF. Circulation and degradation of GIP and GLP-1. Horm Metab Res. 2004;36:761–765.Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity. 2016;24(8):1612–1619. https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025. https://pubmed.ncbi.nlm.nih.gov/39996356/Paika MK. GLP-1 Masterclass; The Weight Equation; Obesity Medicine in Clinical Practice: High-Yield Guide; The Physician's Physique. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Ozempic #GLP1 #Wegovy #EyeHealth #obesitymedicine  Can Ozempic, Wegovy or Mounjaro make you blind? A viewer asked me this, and it deserves an honest, evidence-based answer. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I review every major study on GLP-1 medications and NAION, a rare "stroke" of the optic nerve: The Mass Eye and Ear study that sparked the headlinesThe larger studies from Denmark, Norway and the USThe randomized trials I also cover what the European Medicines Agency, the UK's MHRA and the American Academy of Ophthalmology concluded, plus the separate issue of diabetic retinopathy. You'll learn the real risk in actual numbers, who is at higher risk, and a 5-step eye-safety plan, including the one warning sign that means you go to the ER the same day. TIMESTAMPS0:00 Can GLP-1s make you blind? A viewer's question0:58 Who I am and why this matters1:37 What is NAION? The "stroke" of the optic nerve3:15 How the alarm started: the Mass Eye and Ear study4:16 What the bigger studies found6:13 GLP-1 Masterclass6:51 What regulators and eye specialists concluded8:44 Putting the risk in perspective9:28 The other eye issue: diabetic retinopathy10:41 Free GLP-1 Diet Cookbook11:01 Who is at higher risk?12:16 The 5-step eye-safety plan14:10 What to watch next 📩 FREE GLP-1 Diet Cookbook + Weekly Newsletterhttps://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com REFERENCESStatPearls: Nonarteritic anterior ischemic optic neuropathy. NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK559045/Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. J Neuroophthalmol. 1994;14(1):38-44Hathaway JT, Shah M, Hathaway DB, et al. Risk of NAION in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732-739Grauslund J, Abou Taha A, Molander LD, et al. Once-weekly semaglutide doubles the five-year risk of NAION in a Danish cohort of 424,152 persons with type 2 diabetes. Int J Retina Vitreous. 2024;10:97Simonsen E, Lund LC, Ernst MT, et al. Use of semaglutide and risk of NAION: a Danish–Norwegian cohort study. Diabetes Obes Metab. 2025;27(6):3094-3103Hsu AY, et al. Semaglutide and nonarteritic anterior ischemic optic neuropathy. JAMA Ophthalmol. 2025. doi:10.1001/jamaophthalmol.2025.0349Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or tirzepatide and optic nerve and visual pathway disorders in type 2 diabetes. JAMA Netw Open. 2025;8(8):e2526327DeParis SW, et al. GLP-1 receptor agonists and the risk of NAION: a consensus statement by NANOS and the American Academy of Ophthalmology. Ophthalmology. 2026;133(8)NAION risk with semaglutide: what we know so far (includes Chou et al., 18,657 patients). Eye. 2025. https://www.nature.com/articles/s41433-025-03833-yLiu Z, Raveendran D, Fourlanos S, et al. Rate and risk of NAION with semaglutide use for diabetes and weight loss: a systematic review and meta-analysis. Ophthalmology. 2026;133:589-598European Medicines Agency (PRAC). NAION a very rare side effect of semaglutide. June 2025. https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovyMHRA Drug Safety Update: Semaglutide and risk of NAION. Feb 5, 2026Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221-2232Centers for Disease Control and Prevention. Diabetes and vision lossMarso SP, et al. Semaglutide and cardiovascular outcomes in type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844Vilsbøll T, et al. Semaglutide, reduction in HbA1c and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20(4):889-897Leinung M, Patel N, Bettadahalli S, Paika MK, et al. Benefits of short-term professional continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013Campbell UB, et al. Acute NAION and exposure to phosphodiesterase type 5 inhibitors. J Sex Med. 2015;12(1):139-151 ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Mounjaro #Wegovy #ObesityMedicine Most people think GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound are just for weight loss. The research tells a much bigger story. I'm Dr. Mohammed Paika, board-certified in internal medicine and obesity medicine, with more than 15 years as a hospitalist. In this video I count down 12 evidence-graded health benefits of GLP-1 medications beyond the scale, plus a bonus from the newest cancer research. You'll learn what the major trials show about your heart, liver, kidneys, blood pressure, sleep apnea, inflammation, alcohol cravings, joint pain and blood sugar. I also cover what the latest Alzheimer's trials actually found. Stay for number 1: a major analysis of the SELECT trial found that about two-thirds of the heart protection wasn't explained by weight loss. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS0:00 Why GLP-1s are about more than weight loss1:05 Who I am and why this matters1:56 #12 Blood pressure and blood fats2:42 #11 Less joint pain, more mobility3:52 #10 Fewer alcohol cravings5:00 #9 A healthier liver5:50 #8 Brain health: the honest version6:55 How to protect muscle on a GLP-1 + Masterclass8:42 #7 Sleep apnea and deeper sleep9:40 #6 Fewer medications and diabetes prevention10:35 BONUS: GLP-1s and cancer, the newest research11:38 Free GLP-1 Diet Cookbook12:03 #5 Quieter food noise and steadier blood sugar12:57 #4 Protecting your kidneys13:46 #3 Blood sugar and diabetes control14:35 #2 Cooling down inflammation15:27 #1 Protecting your heart and blood vessels REFERENCES Deanfield J, et al. Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements (SELECT analysis). Lancet. 2025. PMID: 41138739Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure. Lancet. 2021;397:1625-1636Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024;391:1573-1583Eli Lilly. Retatrutide TRIUMPH-4 topline results (press release, Dec 11, 2025; not yet peer-reviewed). https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-averageKosiborod MN, et al. Semaglutide in HFpEF and obesity (STEP-HFpEF). N Engl J Med. 2023;389:1069-1084Hendershot CS, et al. Once-weekly semaglutide in adults with alcohol use disorder. JAMA Psychiatry. 2025;82(4):395-405Klausen MK, et al. Once-weekly semaglutide vs placebo in alcohol use disorder and comorbid obesity. Lancet. 2026. PMID: 42070571Younossi ZM, et al. The global epidemiology of NAFLD and NASH. Hepatology. 2023;77(4):1335-1347Sanyal AJ, et al. Phase 3 trial of semaglutide in MASH (ESSENCE). N Engl J Med. 2025;392:2089-2099Wang W, et al. Semaglutide and first-time diagnosis of Alzheimer's disease in type 2 diabetes. Alzheimers Dement. 2024;20(12):8661-8672evoke and evoke+ Investigators. Oral semaglutide in early-stage symptomatic Alzheimer's disease. Lancet. 2026Lundgren JR, et al. Healthy weight loss maintenance with exercise, liraglutide, or both combined (S-LITE). N Engl J Med. 2021;384:1719-1730Heymsfield SB, Aronne LJ, et al. Bimagrumab plus semaglutide for obesity (BELIEVE). Nat Med. 2026. https://www.nature.com/articles/s41591-026-04204-0Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205Jastreboff AM, et al. Tirzepatide for obesity treatment and diabetes prevention (SURMOUNT-1, 3 years). N Engl J Med. 2025;392:958-971Lauby-Secretan B, et al. Body fatness and cancer — viewpoint of the IARC Working Group. N Engl J Med. 2016;375:794-798(complete list available upon request) ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#Mounjaro #Tirzepatide #GLP1 #WeightLoss #obesitymedicine  Why do two people on the same Mounjaro dose get completely different results? In this video, I break down a study of more than 3,000 people with type 2 diabetes from the SURPASS 1–4 trials. It looked at who is most likely to lose 15% or more of their body weight on tirzepatide (Mounjaro / Zepbound), and why. You'll learn the 7 factors that predicted the biggest weight loss. Several of them are things you can change, sometimes before your first injection. I also cover what newer research says about Ozempic and Wegovy, why real-world results are lower than trial results, and the 6-month check-in that tells you whether you're on track. 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com TIMESTAMPS0:00 Same drug, very different results1:15 Mounjaro vs Zepbound vs Ozempic explained2:19 What the SURPASS study measured3:32 Factor 1: Sex4:36 Factor 2: Age (and muscle loss)6:32 Factor 3: Your starting blood sugar8:36 Factor 4: Your cholesterol9:32 GLP-1 Masterclass10:12 Factor 5: Your other medications11:41 Factor 6: Dose12:34 Factor 7: Race and ethnicity13:29 Surprise: starting weight didn't matter13:58 Does this apply to Ozempic and Wegovy?15:26 The limits of this research16:36 7 steps to improve your odds19:52 Free GLP-1 Diet Cookbook + what's next REFERENCES Małecki MT, Batterham RL, Sattar N, et al. Predictors of ≥15% weight reduction and associated changes in cardiometabolic risk factors with tirzepatide in adults with type 2 diabetes in SURPASS 1–4. Diabetes Care. 2023;46(12):2292-2299. doi:10.2337/dc23-1135Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36.Aronne LJ, Horn DB, Kokkinos AD, et al. Relationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis. Am J Med. 2026;139(7):913-921. doi:10.1016/j.amjmed.2026.03.010Powell W, Song X, Mohamed Y, et al. Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data. Obesity (Silver Spring). 2023;31(10):2482-2492. doi:10.1002/oby.23859Look M, Dunn JP, Kushner RF, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab. 2025;27(5):2720-2729.Sattar N, Frühbeck G, Andreelli F, et al. Weight reduction with tirzepatide varied meaningfully by baseline HbA1c category in adults with overweight or obesity and type 2 diabetes in SURMOUNT-2. Diabetes Care. 2025;48(11):e136-e137. doi:10.2337/dc25-1442Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403.UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity. JAMA Intern Med. 2024.Leidy HJ, Clifton PM, Astrup A, et al. The role of protein in weight loss and maintenance. Am J Clin Nutr. 2015;101(6):1320S-1329S.Mechanick JI, Butsch WS, Christensen SM, et al. Strategies for minimizing muscle loss during use of incretin-mimetic drugs for treatment of obesity. Obes Rev. 2025;26(1):e13841.Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48.Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342-362.⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.

#GLP1 #Ozempic #Zepbound #Wegovy #weightloss  Losing weight on Wegovy, Ozempic, Zepbound, or Mounjaro? What you eat while you're on it matters more than most people realize. In this video, board-certified internal medicine and obesity medicine physician Dr. Mohammed Paika breaks down the 3 nutrition gaps that show up again and again in GLP-1 patients — protein, fiber, and fluids — and the 10 foods that address them, backed by real research on muscle preservation, gut health, and the GLP-1 pathway itself. You'll learn why eating less doesn't automatically mean eating well, what the research says about muscle loss on semaglutide and tirzepatide, and exactly which foods to prioritize so you protect your muscle, support your gut, and get more out of your medication — not just a smaller number on the scale. 🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime AccessComprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.https://www.drmohammedpaika.com 📩 FREE GLP-1 Diet Cookbook + Weekly NewsletterGet weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.https://www.drmohammedpaika.com/newsletter 📚 The Weight Equation & The Physician’s PhysiquePhysician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.https://www.drmohammedpaika.com/books 👥 Metabolic Health Communityhttps://www.skool.com/metabolic-health-community-5316👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKABoard-Certified in Internal Medicine and Obesity MedicineCertified Personal Trainer & Nutrition CoachHelping people understand metabolism, hormones, and sustainable health through evidence-based medicine. Timestamps0:00 Intro — The Mistake That's Sabotaging Your GLP-1 Results2:03 Why What You Eat Matters More Than Ever5:17 The 3 Nutrition Gaps on GLP-1 Medications7:33 #1 Oats8:55 #2 Turkey Breast10:18 #3 Tofu & Edamame11:35 #4 Tuna & Shrimp12:44 #5 Quinoa13:49 #6 Chia Seeds & Flaxseed15:50 #7 Sweet Potatoes17:07 #8 High-Protein Milk18:31 #9 Kefir20:08 #10 Watermelon, Citrus & Coconut Water21:33 The One Rule That Ties It All Together22:06 Final Thoughts References Johnson et al. "Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study." Frontiers in Nutrition, 2025;12.Bikou A, et al. "A systematic review of the effect of semaglutide on lean mass: insights from clinical trials." Expert Opinion on Pharmacotherapy, 2024;25(5):611-619.Look M, et al. "Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study." Diabetes, Obesity and Metabolism, 2025.Hirasawa T, et al. "Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120." Nature Medicine, 2005;11(1):90-94.de Jong et al. "Dietary fibers to boost endogenous GLP-1 secretion and satiety: a scoping review." Frontiers in Endocrinology, 2026.Tolhurst G, et al. "Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2." Diabetes, 2012;61(2):364-371.Longland TA, et al. "Higher compared with lower dietary protein during an energy deficit..." American Journal of Clinical Nutrition, 2016.Ogilvie AR, et al. "Higher protein intake during caloric restriction improves diet quality and attenuates loss of lean body mass." Obesity, 2022;30(11).Nutrition figures throughout: USDA FoodData Central. ⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.